Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch
NCT ID: NCT01191359
Last Updated: 2013-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
66 participants
INTERVENTIONAL
2010-01-31
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever
NCT00310466
Open Label Safety Study of a Birch Pollen Allergen Extract
NCT00818181
Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis
NCT01731249
Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1
NCT00396149
Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients
NCT00410930
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sublingual administration
oral immunotherapy with drops applied once daily by single dose containers (200 STU per dose)
oral immunotherapy
orally applied specific immunotherapy
vestibular administration
oral immunotherapy with drops applied by single dose containers (200 STU per dose)
oral immunotherapy
orally applied specific immunotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
oral immunotherapy
orally applied specific immunotherapy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Positive skin prick test to birch
* Positive specific IgE to birch
Exclusion Criteria
* Previous treatment by immunotherapy with birch or a cross-reactingtree pollen allergen within the previous 5 years
* Concomitant SLIT with any allergen
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ALK-Abelló A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Bieber, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Universitäsklinik Bonn, Dermatology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitätsklinik Bonn, Dermatology
Bonn, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SP-B-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.